Pharmaceutical filing citing a Journal of Dermatological Treatment paper — Turn Therapeutics, 2026-05-27
Turn TherapeuticsTurn TherapeuticsNASDAQ TTRX
Filings SEC · Quote Yahoo cited a paper published in the Journal of Dermatological Treatment in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was recorded. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Turn Therapeutics on 2026-05-27 were 7.01 Reg FD disclosure · 9.01 financial statements·attached documents. The company cited a paper published in Journal of Dermatological Treatment in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
The publication, titled “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen Bresnick, M.D., a practicing physician, researcher, and advisor to the Company.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which only read the abstract, cannot provide an answer.
The scope of the paper mentioned in the abstract is limited to this.
The paper title is Effects of extended-release topical polyhexanide in a Staphylococcus aureus–induced murine dermatitis model characterized by IL-36 expression and it was published in Journal of Dermatological Treatment on 2026-05-26. The authors are affiliated with Io Therapeutics (United States) and IS Practice. The summary at the beginning of the paper is called abstract. This article only read up to that point. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, and thus differs in quality from a full-text reading and original judgment.
It is an animal experiment applying a sustained-release polyhexanide ointment to mice with skin inflammation caused by Staphylococcus aureus. A skin inflammation model with high levels of the inflammatory signaling molecule IL-36 was created, and an evaluator blinded to the treatment assigned scores using the Atopic Dermatitis Severity Index. The result showed lower severity in the group that received the ointment. This is a mouse experiment. Since part of the abstract is missing, the number of animals and the score difference cannot be determined from the abstract alone.
The abstract does not answer; it remains in the main text and the appendix. This text, which does not go there, leaves the blank as it is. Readers compare the two citations above to determine which sentence in the abstract corresponds to the excerpt cited by the company.
A month later, the stock price was within the top quarter of the sample.
The portion of returns not explained by market-wide movements is called excess return. Dates are recorded as trading days, counting only days when the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess returns for the day of the regulatory filing and the following month in this case are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +6.2% | Degree already moved before the filing |
| regulatory filing day | −1.5% | filing day or first trading day thereafter |
| cumulative +1~+5 trading days | +13.7% | one week |
| cumulative +1~+20 trading days | +30.8% | one month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +30.8% in this case is within the top quarter, corresponding to the 94% position from the bottom among 142 samples.
| sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −7.4% | +5.5% | +18.7% | +30.8% |
Half of the sample falls between the two middle marks in the table. Check the table to see whether this case falls inside or outside of that range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules to apply to future cases.
After the filing, the company submitted these documents.
After the filing date, this company submitted three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. The details of what occurred are read in the original text via each link.
- 2026-06-01 8-K Item 7.01, 9.01 — Reg FD disclosure · financial statements · exhibits
- 2026-06-03 8-K Item 7.01, 9.01 — Reg FD disclosure · financial statements · exhibits
- 2026-07-07 8-K Item 7.01, 9.01 — Reg FD disclosure · financial statements · exhibits
What this article does not answer
This article, which reads only abstracts, cannot answer how the paper reevaluated what, by what method, and to what extent. How many times the paper cited by the company was cited afterward can be checked again via the citation count on OpenAlexOpenAlex
Data source · Website. What will be seen next is whether the company's next 8-K again cites the same paper.
Term Explanation
- 8-K
- A periodic report submitted to the U.S. Securities and Exchange Commission when a listed company has something to inform its shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of this company alone, excluding the portion influenced by the entire market rising or falling.
- Trading day
- A date counting only the days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the methods.